Clinical trials: Geographic Atrophy
Dry AMD, Stargardt Disease 1
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.
- Trial name
- MADEOS (NCT03297515)
- Testing
- Madeos
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Ophthalmos Research and Education Institute
Geographic Atrophy
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy
The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07570355
- Testing
- Pterygopalatine ganglion stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic…
- Trial name
- NCT04607148
- Testing
- Galegenimab
- Where
- 48 sites in United States
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
Geographic Atrophy, Dry Age Related Macular Degeneration
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration
This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD).
- Trial name
- GA-PRP (NCT07428798)
- Testing
- Subtenon Autologous Platelet-Rich Plasma Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Geographic Atrophy Secondary to Age-related Macular Degeneration
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
- Trial name
- NCT07214740
- Testing
- APL-2, Pegcetacoplan
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Dry Macular Degeneration
Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration
This will be an open-label, non-randomized multi-center study of adipose stem cell (ASC) implantation. ASCs will be derived from the patient's adipose or fat.
- Trial name
- NCT02024269
- Testing
- Adipose Derived Stem Cells
- Where
- United States
- Sponsor
- Bioheart, Inc.
Geographic Atrophy
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD.
- Trial name
- NCT05019521
- Testing
- Danicopan
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 365 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Age-related Macular Degeneration (AMD)
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues.
- Trial name
- NCT02445313
- Testing
- Nidek MP-3
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Doheny Image Reading Center
Macular Edema, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT04635800
- Testing
- MHU650
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Geographic Atrophy
Evolution and Risk Factors Associated With Geographic Atrophy Progression
Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly…
- Trial name
- GAIN (NCT01694095)
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut de la Macula y la Retina
Age-Related Macular Degeneration, Geographic Atrophy
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Trial name
- JOURNEY (NCT06087458)
- Testing
- VOY-101
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Geographic Atrophy of the Macula, Macular Degeneration
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
- Trial name
- SIGLEC (NCT05839041)
- Testing
- AVD-104, Avacincaptad
- Where
- 56 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aviceda Therapeutics, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
Oral Postbiotics in Patients With Macular Atrophy
A pilot study to evaluate the safety and efficacy of oral therapy with Postbiotics in patients with geographic atrophy secondary to age-related macular degeneration, myopia, or angioid streaks.
- Trial name
- REVERS-GA (NCT05391074)
- Testing
- postbiotics (IGENH35.3A), vitamins (AREDS formulation and recommended daily dose)
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Institut de la Macula y la Retina